Coreg
Product Images NDC 68151-5049

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Coreg (NDC 68151-5049). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carvedilol Phosphate Chemical Structure (Coreg Cr Spl Graphic 01)

Chemical structure diagram of carvedilol phosphate hemi-hydrate, the active ingredient in COREG CR by Carilion Materials Management, showing molecular components including phosphate and water molecules.*

FDA Label Image

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Coreg Cr Spl Graphic 02)

A line graph showing mortality percentage over a 21-month period comparing Carvedilol and Placebo groups. The graph illustrates lower mortality in the Carvedilol group compared to Placebo, with a p-value of 0.0014 indicating statistical significance.*

FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Coreg Cr Spl Graphic 03)

A horizontal forest plot depicting hazard ratios across various patient subgroups, such as gender, age, race, diabetic status, ischemic status, heart rate, systolic blood pressure, and spironolactone use. Each subgroup is represented by a dot with confidence intervals along a scale from 0.0 to 2.0, with a vertical reference line at 1.0, showing comparative risk levels.*

FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Coreg Cr Spl Graphic 04)

A survival curve chart depicting % mortality over 24 months comparing Carvedilol and Placebo groups. The graph shows two lines, with Carvedilol demonstrating lower mortality percentages than Placebo. A p-value of 0.03 is indicated, suggesting statistical significance in the difference between the groups.*

FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Coreg Cr Spl Graphic 05)

A forest plot chart showing hazard ratios for various patient subgroups related to post-myocardial infarction (MI) clinical characteristics. The x-axis represents hazard ratios ranging approximately from 0.4 to 1.3. Patient subgroups include age, sex, timing of randomization post-MI, prior intravenous/oral beta-blocker use, Killip classification, thrombolytic therapy, PTCA for MI, heart failure history, diuretic use during MI, angina status, hypertension, diabetes, heart rate, and systolic blood pressure. Each subgroup has a point estimate with confidence intervals displayed on either side of a reference line at hazard ratio 1.0.*

FDA Label Image

Figure 5. Changes From Baseline In Systolic Blood Pressure And Diastolic Blood Pressure Measured By 24-hour Abpm (Coreg Cr Spl Graphic 06)

Two line graphs showing change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) over 24 hours after a morning dose of COREG CR at 20 mg, 40 mg, and 80 mg strengths. The graphs display smoothed trend lines indicating blood pressure changes by dosage over time.*

FDA Label Image

Label Image (Lbl681515049)

Label of COREG CR (Carvedilol Phosphate) 20 mg extended-release capsules. The label includes manufacturer information (GSK), lot number, expiration date (07/14), prescription-only designation, and a barcode with the number 0000005049. The label is from Carilion Materials Management.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.